title: New molecular targets against cervical cancer.
abstract: Cervical cancer is the third most commonly diagnosed cancer worldwide and the fourth leading cause of cancer death in women. Major advances but still insufficient achievements in the treatment of locally advanced and high-risk early stage patients have occurred in the last decade with the incorporation of concurrent cisplatin with radiation and, lately, gemcitabine added to cisplatin chemoradiation. Despite a number of clinical studies incorporating molecular-targeted therapy as radiosensitizers being in progress, so far, only antiangiogenic therapy with bevacizumab added to cisplatin chemoradiation has demonstrated safety and shown encouraging results in a Phase II study. In advanced disease, cisplatin doublets do not have a great impact on the natural history of the disease with median survival rates not exceeding 13 months. The first Phase III study of bevacizumab, added to cisplatin or a non-cisplatin-containing doublet, showed significant increase in both overall survival and progression-free survival. Further studies are needed before bevacizumab plus chemotherapy can be considered the standard of care for advanced disease. Characterization of the mutational landscape of cervical cancer has already been initiated, indicating that, for now, few of these targetable alterations match with available agents. Progress in both the mutational landscape knowledge and developments of novel targeted therapies may result in more effective and individualized treatments for cervical cancer. The potential efficacy of knocking down the key alterations in cervical cancer - E6 and E7 human papillomavirus oncoproteins - must not be overlooked.
authors.affiliation: Unit of Biomedical Research in Cancer, Instituto de Investigaciones Biomedicas UNAM/Instituto Nacional de Cancerologia, Mexico City, Mexico ; ISSEMyM Cancer Center, Toluca, Mexico.
authors.forename: Alfonso
authors.initials: A
authors.lastname: Duenas-Gonzalez
authors.affiliation: Medical Oncology Service, ABC Medical Center, Mexico City, Mexico.
authors.forename: Alberto
authors.initials: A
authors.lastname: Serrano-Olvera
authors.affiliation: Division of Clinical Research, Instituto Nacional de Cancerologia, Mexico City, Mexico.
authors.forename: Lucely
authors.initials: L
authors.lastname: Cetina
authors.affiliation: Division of Clinical Research, Instituto Nacional de Cancerologia, Mexico City, Mexico.
authors.forename: Jaime
authors.initials: J
authors.lastname: Coronel
keywords: HPV; bevacizumab; cervical cancer; molecular-targeted therapy